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Abstract 
Background: Rheumatoid arthritis (RA) is characterized by excessive synovial inflammation. Cyclooxygenase‑2 (COX‑
2) is an enzyme that catalyzes the conversion of arachidonic acid (AA) into prostaglandins. Epithelium‑specific Ets 
transcription factor‑1 (ESE‑1) was previously demonstrated to upregulate COX‑2 in co‑operation with nuclear factor 
kappa B (NFκB) in macrophages and chondrocytes. However, the role of ESE‑1 in RA pathology has remained unclear. 
In this study, we aimed to elucidate the relationship between ESE‑1 and COX‑2 in RA synovial fibroblasts (RASFs) using 
a HD‑Ad‑mediated knockdown approach.
Results: ESE‑1 and COX‑2 were induced by IL‑1β in RASFs that corresponded with an increase in PGE2. Endogenous 
levels of ESE‑1 and COX‑2 in human RASFs were analyzed by RT‑qPCR and Western blot, and PGE2 was quantified 
using competitive ELISA. Interestingly, knockdown of ESE‑1 using helper‑dependent adenovirus (HD‑Ad) led to a 
significant upregulation of COX‑2 at a later phase of IL‑1β stimulation. Examination of ESE‑1 intracellular localization 
by nuclear fractionation revealed that ESE‑1 was localized in the nucleus, occupying disparate cellular compartments 
to NFκB when COX‑2 was increased. To confirm the ESE‑1‑COX‑2 relationship in other cellular systems, COX‑2 was also 
measured in SW982 synovial sarcoma cell line and ESE‑1 knockout (KO) murine macrophages. Similarly, knockdown of 
ESE‑1 transcriptionally upregulated COX‑2 in SW982 and ESE‑1 KO murine macrophages, suggesting that ESE‑1 may 
be involved in the resolution of inflammation.
Conclusion: ESE‑1 acts as a negative regulator of COX‑2 in human RASFs and its effect on COX‑2 is 
NFκB‑independent.
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Background
Rheumatoid arthritis (RA) is a systemic autoimmune dis-
ease characterized by the progressive destruction of the 
joints due to excessive inflammation in the synovium, 
which can lead to deformities and loss of joint function 
in severe cases. Inflammation in the RA synovial tissue is 
perpetrated by the production of inflammatory cytokines 
and secreted mediators from infiltrating immune cells 
and activated synovial fibroblasts [1]. Prostaglandins 
(PGs) are key mediators responsible for RA symptoms of 
pain and swelling [2]. Synthesis of PG requires conver-
sion of arachidonic acid released from cell membranes to 
prostaglandin H2 (PGH2), the critical step of which is cat-
alyzed by cyclooxygenase-2 (COX-2), also known as the 
PGH2 synthase. PGH2 is further metabolized to bioactive 
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forms such as PGE2, prostacyclin, prostaglandin D2, and 
prostaglandin F2α, by their respective synthases in dif-
ferent cell types [2, 3]. COX-2 is highly expressed in the 
RA synovial lining due to the persistent presence of pro-
inflammatory cytokines such as IL-1β, TNF-α, and IL-6, 
and is a key biosynthetic enzyme regulating PG produc-
tion in the synovium [4, 5]. PGE2 is the major PG that is 
generated by chondrocytes and synovial fibroblasts [6], 
and clinical responses to non-steroidal anti-inflamma-
tory drugs (NSAIDs) have been shown to correlate with 
reduced levels of PGE2 in the synovial fluid [7, 8]. COX-2 
inhibitors such as celecoxib effectively control arthritis 
symptoms [8].
COX-2 gene activation is complex and employs numer-
ous regulatory factors specific to different stimuli, as 
exemplified by the COX-2 promoter which contains two 
NFκB motifs, two activator protein 1 (AP-1) sites and two 
cAMP-response elements (CREs) among others [9]. Sev-
eral Ets factors have also been shown to regulate COX-2 
expression, including Ets-1 [10], Pea3 [11] and PU.1 
[12], and Elk1 [13] in different tissue contexts. Ets fam-
ily of transcription factors are characterized by the highly 
conserved E26 transformation-specific (Ets) DNA bind-
ing domain, which recognizes GGAA/T core consensus 
sequence within the promoter and enhancer regions 
of target genes [14]. Unlike most Ets factors which are 
expressed in hematopoietic cells, however, a subgroup 
of Ets proteins called epithelium-specific Ets factors 
(ESE’s) has epithelium-restricted expression pattern 
under basal conditions. Interestingly, ESE-1, the proto-
type of ESE subfamily, is highly sensitive to inflammatory 
stimulation [15], where it was found to be expressed in 
the human RA synovial tissue [16]. It was also transcrip-
tionally upregulated by proinflammatory stimuli such as 
IL-1β, TNF-α, or LPS in the resident cell types including 
synovial fibroblasts, chondrocytes, osteoblasts, and mac-
rophages, typically displaying a peak expression between 
2–6 h and dissipation by 24 h in most cells [16]. ESE-1, or 
Elf3 in mice, was similarly found to transactivate COX-2 
promoter in murine macrophages and human chondro-
cytes in cooperation with NFκB [17], suggesting its criti-
cal role in RA pathogenesis. However, initial analyses 
had revealed ESE-1 to be predominantly expressed in the 
cytoplasm of the cells [16], leaving discrepancies in how it 
might function as a transcription factor in situ. Addition-
ally, the prolonged expression of ESE-1 mRNA in RASFs 
beyond 24  h of IL-1β stimulation unlike in other cell 
types has left the relationship between ESE-1 and COX-2 
in RASFs elusive. As RASFs and synovial macrophages 
are prominent cell types present in the terminal layer of 
the hyperplastic synovial tissue which secrete inflamma-
tory cytokines and matrix-degrading enzymes [18, 19], 
elucidation of the role of ESE-1 in COX-2 regulation is 
important to gain better understanding of the molecular 
events that occur in RA synovial tissues.
Previous studies primarily focused on investigating 
functional significance of ESE-1 by ESE-1 overexpression, 
where ESE-1 cDNA was transfected into cell lines along 
with luciferase constructs to investigate the transactiva-
tion of ESE-1 on its target genes. However, ectopic gene 
expression can lead to supraphysiological levels of the 
gene of interest, as well as cell toxicity from the transfec-
tion procedure itself. Also, overexpression by transfec-
tion may not accurately reflect the temporal behaviour 
of a protein, and may thus lead to artificial interaction or 
co-localization of proteins that do not normally co-exist 
under physiological conditions. ESE-1 overexpression 
could also have accompanied co-induction of its other 
target genes, giving rise to confounding results. There-
fore, we sought to elucidate the relationship between 
ESE-1 and COX-2 in human RASFs using a knockdown 
approach with helper-dependent adenoviral (HD-Ad) 
vector, which has all of the viral genes removed to ren-
der it much less immunogenic than conventional ade-
noviruses [20, 21], and in Elf3 knockout mouse bone 
marrow-derived macrophages (BMDMs) to avoid side 
effects from transfection- or transduction-mediated gene 
manipulation. In this study, we show for the first time 
that ESE-1 negatively regulates COX-2 in human RASFs.
Methods
Reagents
DMEM, RPMI, fetal bovine serum (FBS) and l-glu-
tamine were purchased from Gibco Life Technologies 
Ltd., Burlington, Ontario, Canada. Penicillin/streptomy-
cin, phosphate buffered saline (PBS) were from Wisent, 
St. Bruno, Quebec, Canada. Human recombinant IL-1β 
was product of R&D Systems (Minneapolis, MN, USA), 
and LPS endotoxin (Escherichia coli, serotype O128:B12) 
and DEAE-Dextran hydrochloride of Sigma (Oakville, 
Ontario, Canada), while murine IL-4 was from Pepro-
tech, Quebec, Canada. Antibodies used in this study 
were: COX-2 rabbit polyclonal antibody from Thermo 
Fisher Scientific (Burlington, Ontario, Canada), and 
COX-2 (C-20) goat polyclonal, NFκB p65 (C-20), p50 
(H-119) and Lamin A (H-102) rabbit polyclonal anti-
bodies from Santa Cruz (Dallas, TX, USA). ESE-1 rabbit 
monoclonal antibody was produced in our laboratory in 
collaboration with Epitomics, Burlingame, CA, USA [22]. 
Hsp90 rabbit polyclonal and β-actin mouse monoclonal 
antibodies were purchased from Cell Signaling Technol-
ogy (Whitby, Ontario, Canada).
Preparation of RASFs
Synovial tissues were obtained at the time of joint 
replacement surgery from patients with RA who fulfilled 
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the revised American Rheumatism Association criteria 
for this disease [7]. Experiments were carried out accord-
ing to a protocol that was approved by the Institutional 
Review Board in Vanderbilt University, Nashville, TN, 
and patient informed consent was obtained. RASF were 
prepared as previously described [9]. Briefly, minced syn-
ovial tissues were digested overnight with 1 mg/ml colla-
genase (Type I, Sigma, St. Louis, MO, USA) in DMEM in 
a humidified 5 % CO2 incubator at 37 °C and the isolated 
cells were cultured in 175  cm2 culture flasks in DMEM 
supplemented with 20 % FBS, l-glutamine (2 mM), peni-
cillin (100 units/ml) and streptomycin (100  μg/ml). At 
greater than 95 % confluency, the adherent RSF were pas-
saged by digestion with 0.05  % trypsin/EDTA and used 
for cell culture experiments.
Cell culture
Human synovial sarcoma and lung adenocarcinoma 
cell lines SW982 and A549 were obtained from Ameri-
can Type Culture Collection, Rockville, MD, and were 
cultured in DMEM supplemented with 10  % FBS and 
100  IU/mL penicillin, and 100  μg/mL streptomycin in 
5 % CO2 at 37 °C. Cells were starved in serum-deprived 
medium containing 0.5 % FBS, in which transduction and 
cytokine stimulation were also performed.
Infection of cells with helper‑dependent adenovirus 
(HD‑Ad)
ESE-1 gene was knocked down in human synovial fibro-
blasts and SW982 cells using shRNA helper-dependent 
adenoviral vector expressing two shRNAs prepared as 
previously described [23, 24], with added modifications 
from [25]. Briefly, cells were seeded at 100,000 cells per 
well in growth medium on 6-well plates a day prior to 
transduction, and 5000 virus DNA particles per cell 
equivalent of 100 MOI were complexed with 520.5  ng 
DEAE-Dextran by incubation for 30  min at room tem-
perature in 0.5 % FBS DMEM. The DEAE-virus mixture 
was added to cells by replacing the growth medium. 
C4HSU empty vector was used as control. The cells were 
incubated for 2 h in a 5 % CO2 at 37 °C, after which 20 % 
FBS DMEM was added to achieve a final concentration 
of 10 % FBS. The cells were then incubated for additional 
48  h, and the medium was removed and replaced with 
0.5 % FBS DMEM for 24 h starvation before being stimu-
lated with 10 ng/mL IL-1β.
RNA isolation and real‑time quantitative PCR (RT‑qPCR)
Total RNA was isolated using GE Illustra RNAspin Mini 
Kit (GE Healthcare Life Sciences, Baie-D’Urfe, Quebec) 
as per manufacturer’s instructions. For real-time quan-
titative PCR, after spectrophotometry quantification, 
1 µg of RNA was reversed transcribed in a final volume 
of 20 μL using Superscript VILO Mastermix with Super-
script III (Invitrogen, Carlsbad, CA) and the resulting 
cDNA template (10 ng) was used for qPCR reaction using 
Power SYBR Green PCR Master Mix from Life Tech-
nologies (Burlington, Ontario, Canada). ViiA™7 Real-
Time 384-well PCR System from Life Technologies was 
used for the amplification and analysis. For relative ΔΔCt 
quantification, qPCR signals were normalized using 
GAPDH and fold changes were calculated according to 
Livak and Schmittgen [26]. The primer sequences used 
for human and mouse samples are provided in Additional 
file 1: Table S1.
Cytoplasmic nuclear fractionation and Western blot
Nuclear and cytoplasmic extracts were prepared from 
human RASFs by nuclear/cytoplasmic separation as 
previously described [27]. In summary, cells grown in 
10 cm dishes were washed twice with ice-cold PBS, and 
pelleted cells were resuspended in 900 µL of hypotonic 
buffer containing 0.1 % NP-40 in PBS containing protease 
inhibitors (Roche; Mississauga, Ontario, Canada) and 
triturated five times, after which they were immediately 
centrifuged at 500×g at 4  °C. The supernatant was col-
lected and designated as the cytoplasmic extract, while 
the pellet was washed once with 1  mL of 0.1  % NP-40 
PBS buffer, re-centrifuged, and lysed in 180 µL 6 × SDS 
sample buffer [2  % (w/v) SDS, 58.3  mM Tris–HCl (pH 
6.8), 6  % (v/v) glycerol, 5  % (v/v) 2-β-mercaptoethanol, 
0.02  % (w/v) bromophenol blue] and was designated as 
the nuclear extract. The nuclear extract was sonicated 
at Level 2 on Misonix 3000 sonicator for 5–10 s. Lysates 
were separated by electrophoresis on 10  % SDS-PAGE 
gel, and transferred to nitrocellulose membrane (Amer-
sham; GE Healthcare, Mississauga, Ontario, Canada). 
Membranes were blocked with 5  % (w/v) nonfat milk 
in TBST (50 mM Tris–Cl pH 7.5, 150 mM NaCl, 0.05 % 
Tween-20) for 1  h at room temperature and probed for 
ESE-1 (1:3000), COX-2 (1:500), Hsp90 (1:1000), β-actin 
(1:4000), or Lamin A (1:500) overnight at 4  °C. Protein 
signals were detected with HRP-conjugated secondary 
antibodies at a dilution of 1:4000 using ECL Western 
blotting detection system (Amersham Pharmacia Bio-
tech, Baie-D’Urfe, Quebec, Canada).
Prostaglandin E2 (PGE2) quantification
PGE2 was quantified using a competitive binding ELISA 
kit (R&D Systems) according to the manufacturer’s pro-
tocol. Cell medium was centrifuged to remove particu-
lates and the supernatant was diluted threefold before 
the assay. The plate was read with plate reader VersaMax-
PLUS ROM v1.21 with SoftMax Pro v5.3b12 software at 
the absorbance of 450  nm with wavelength correction 
at 540 nm to correct for the optical imperfections in the 
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plate. The concentration of PGE2 was calculated against a 
standard curve ranging from 0 to 2500 pg/mL.
ESE‑1/Elf3 knockout mice and bone marrow‑derived 
macrophage culture
Elf3-/- mice on a C57BL/6 background were housed in 
pathogen-free condition at Toronto Centre for Phenog-
enomics (TCP), Toronto, Canada, and all procedures 
were approved by the Toronto Centre for Phenogenom-
ics Animal Care Committee (Animal Use Protocol 
#0062). Bone marrow was flushed from femur and tibia 
of Elf3−/− mice and wild-type littermates into single 
cell suspension and cultured in 20 % L-929 conditioned 
media containing for 7 days as previously described [28]. 
Wild-type littermates were used as controls. The purity 
of bone marrow-derived macrophages was measured by 
flow cytometry with CD11b and F4/80 following meth-
ods from [10]. 4 × 105 of mature BMDMs were subjected 
to 100 ng/mL LPS or 10 ng/mL IL-4 for 18 h to drive M1 
and M2 polarization, respectively.
Statistical analysis
Statistical analysis was performed by two-tailed Student’s 
t test with Welch’s corrections for unequal variances 
where appropriate, or by one-way paired ANOVA for 
multiple comparisons with Tukey’s post-test or Bonfer-
roni’s post-test for selected pairs using GraphPad Prism 
5.03 (GraphPad Software, Inc., La Jolla, CA, USA). P 
values of less than 0.05 were considered statistically 
significant.
Results
ESE‑1 and COX‑2 are induced by IL‑1β in human RASFs
ESE-1 was previously shown to be rapidly upregulated 
by proinflammatory stimuli in human RASFs and main-
tained up to 24 h [15, 16]. To investigate its relationship 
to COX-2 expression, we stimulated primary RASFs 
with 10 ng/mL human IL-1β and quantified the amount 
of ESE-1 and COX-2 mRNA by RT-qPCR (Fig.  1a). We 
observed that ESE-1 mRNA expression peaked around 
6 h and was reduced slightly at 24 h. Transcriptional lev-
els of COX-2, on the other hand, showed gradual increase 
until 6 h and downregulation at 24 h post IL-1β stimula-
tion. Protein levels of ESE-1 varied among RA patients, 
though a representative is shown in Fig.  1c, indicating 
heterogeneity of the patient population and potentially 
the presence of other factors which may modulate ESE-1 
expression (Additional file  2: Figure S1A). COX-2 pro-
tein, however, accumulated over time in most patients 
as previously shown [29] (Additional file 2: Figure S2B), 
which correlated with increase in PGE2 concentration 
(Fig. 1b).
RASFs can be effectively transduced by helper‑dependent 
adenovirus (HD‑Ad)
Helper-dependent adenovirus (HD-Ad) provide an attrac-
tive alternative means of gene delivery to non-viral vectors 
or other virus types, by its high carrying capacity of 37 kb 
and low immunogenicity from having all its viral coding 
sequences removed [20, 21]. HD-Ads have been success-
fully produced and used in our laboratory as a potential 
tool for cystic fibrosis (CF) gene therapy [30], as well as a 
research tool to knockdown ESE-1 in a number of studies 
[23, 24]. However, similar to other adenoviruses, HD-Ad 
requires specific receptors to mediate viral attachment 
and gene transfer, notably the coxsackie virus and adeno-
virus receptor (CAR), which the fibroblasts are known 
to be lacking [31]. As expected, transduction with virus 
alone in human RASFs proved ineffective irrespective of 
viral dose (Fig. 2a), despite yielding close to 100 % trans-
duction in A549 lung adenocarcinoma cell line (data not 
shown). Non-covalent complexing of recombinant adeno-
virus with cationic molecules, however, has been demon-
strated to significantly increase viral attachment and thus 
the efficiency of gene transfer by neutralizing the net neg-
ative surface charge on virus particles and the cell mem-
brane [25, 32]. In an attempt to optimize viral infection 
in human RASFs, therefore, we complexed HD-Ad with 
DEAE-Dextran, which resulted in 100 % cells being trans-
duced at 100 MOI, with the expression lasting for more 
than 96 h. We were able to achieve up to 90 % knockdown 
of ESE-1 with HD-Ad carrying shESE-1 construct using 
this infection protocol (Fig. 2b). Although it was inevita-
ble that the virus led to some degree of inflammation and 
ESE-1 activation, by 72 h from the initial exposure to virus 
particles, the background PGE2 and COX-2 expression 
were comparable to basal levels prior to IL-1β stimulation. 
There was also minimal cell toxicity, if any, conferring a 
significant advantage over transfection. This indicates that 
with optimization with charge-neutralizing polymers such 
as DEAE-Dextran, HD-Ad can be an effective gene deliv-
ery tool for hard-to-transduce cell types such as immune 
cells and fibroblasts, and to study immune-responsive or 
cell survival genes that can be affected by transfection.
Knockdown of ESE‑1 leads to upregulation of COX‑2 
and increased PGE2 production
In all patient RASF studied, knockdown of ESE-1 led 
to a significant upregulation of COX-2 at both RNA 
(Fig.  2b) and protein (Fig.  2d) levels. This correlated 
with increased concentration of PGE2 in the cell media 
(Fig.  2c), indicating functional significance of ESE-1 on 
COX-2 activity. There was also a recognizable hetero-
geneity in different patient RASFs resulting in different 
basal expression of ESE-1 following HD-Ad transduction 
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(Additional file  2: Figure  1c), but all showed similar 
trends of upregulated COX-2 following ESE-1 knock-
down. Interestingly, however, ESE-1 knockdown had no 
effect on COX-2 basal level of mRNA expression or early 
phase of induction, and the effect of ESE-1 knockdown 
on COX was only visible at 24-hour time point (Fig. 2e). 
Similarly, while adenovirus binding to cultured synovio-
cytes is known to trigger COX-2 expression through the 
MAPK pathway, this subsides by 24  h [33] and in our 
study, transduced cells were stimulated with IL-1β 72  h 
after initial exposure to the virus when both COX-2 and 
PGE2 were comparable to the basal levels, thus minimiz-
ing confounding results from the inflammatory reaction 
to the viral vector. Still, C4HSU empty vector control 
virus was used in all experiments to account for the basal 
inflammatory response to the viral vector itself. Addi-
tionally, knockdown of ESE-1 had no effect on metal-
loprotease activity in RASFs, as shown by insignificant 
changes in MMP-1 or -13 mRNA expression (Additional 
file 2: Figure S2), indicating that ESE-1 may be a specific 
effector for resolving inflammatory responses.
ESE‑1 is localized in the nucleus
ESE-1 was previously detected in the cytoplasm by 
immunostaining of RA patient tissue sections [16]. How-
ever, cytoplasmic/nuclear fractionation of activated 
human RASFs in in vitro following 24 h IL-1β stimulation 
revealed nuclear presence of ESE-1 (Fig. 3a, b), which was 
also consistent following shESE-1 HD-Ad viral transduc-
tion, where nuclear decrease in ESE-1 led to cytoplas-
mic increase in COX-2 (Fig.  3d). Furthermore, despite 
findings of ESE-1 cooperating with NFκB to transacti-
vate target genes such as iNOS in endothelial cells [34] 
and COX-2 in macrophages [17], NFκB was localized in 
the cytoplasm by 24  h post IL-1β stimulation in RASFs 
(Fig. 3c, d). This was consistent with the previous finding 
where NFκB activated by IL-1β in RASFs resolved and 































































Fig. 1 ESE‑1 and COX‑2 are induced by IL‑1β in human RASFs. a Changes in ESE‑1 and COX‑2 transcriptional levels in human patient RASFs (n = 5) 
during IL‑1β (10 ng/mL) stimulation by quantitative RT‑PCR normalized to GAPDH. b Quantification of prostaglandin E2 (PGE2) in the culture media 
of human RASFs (n = 6) stimulated with 10 ng/mL of IL‑1β for the designated time points. c Representative Western blot from four independent 
patients showing changes in ESE‑1 and COX‑2 at protein level, using Hsp90 as a loading control. Bars show mean ± SEM, *P < 0.05, **P < 0.01, 
***P < 0.001











































































































































Fig. 2 Knockdown of ESE‑1 leads to increased COX‑2 and PGE2 production in RASF. a Representative picture of human RASFs successfully trans‑
duced with helper‑dependent adenovirus containing EGFP construct (HD‑Ad‑EGFP) with and without DEAE‑Dextran. b Knockdown of ESE‑1 leads 
to the transcriptional upregulation of COX‑2 following 24 h of IL‑1β stimulation (n = 6). The cells were incubated in the presence of HD‑Ad and 
DEAE‑Dextran complex for 48 h and starved in 0.5 % FBS DMEM for 24 h prior to incubation with IL‑1 β. Scale bar shows 100 μm. c Transcriptional 
upregulation of COX‑2 is accompanied by increased production of PGE2 (n = 6). d Representative Western blot showing changes in ESE‑1 and COX‑2 
proteins in RASFs transduced with control (C4HSU) or shESE‑1 HD‑Ad. Bars show the mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, by one‑way 
ANOVA Bonferroni’s post‑test. (E) Time point analysis of ESE‑1 and COX‑2 transcriptional levels (n = 5) during IL‑1β stimulation after C4HSU or 
shESE‑1 HD‑Ad viral transduction. ns not significant, *P < 0.05, ***P < 0.001
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Therefore while NFκB may be responsible for the tran-
scriptional upregulation of ESE-1 [23], it seems unlikely 
that NFκB is involved at the 24 h time point when ESE-1 
knockdown enhances COX-2 expression. Nuclear locali-
zation of ESE-1 is in alignment with its known function 
as a transcription factor, and it may regulate other genes 
implicated in COX-2 regulation.
SW982 cell line shows different pattern of ESE‑1 expression 
from human primary RASFs
The transcriptional expression pattern of ESE-1 in 
response to IL-1β has been studied in numerous non-
epithelial cell lines, including human chondrocytes (T/
C28a2, C28/I2, and C20A4), osteoblasts (LB-12), mono-
cytes (THP-1), gliomas (U-138 MG and U-373 MG), and 
endothelial cells (HUVECs), where ESE-1 was shown 
to be one of the few Ets factors that were specifically 
responsive to IL-1β-mediated activation, with typi-
cal induction pattern of peak expression between 2–6 h 
and dissipation by 24  h in most cell types [15–17, 34]. 
Studies have shown that SW982 synovial sarcoma cell 
line is representative of human primary synovial fibro-
blasts [35, 36]. However, the expression pattern of ESE-1 
in SW982, where ESE-1 peaked at 2  h and underwent 
drastic downregulation at 24  h (Fig.  4a), and protein 
expression peaking at 6  h and subsequently undergoing 
degradation (Fig. 4b), was different from that of RASFs, 
indicating that it is not a good representative cell line for 
our purposes. The knockdown of ESE-1 still had a vis-
ible effect on COX-2 upregulation at only 24 h (Fig. 4c), 
when ESE-1 protein was minimally present. p65 (= RelA) 
also dissipated by 24 h of IL-1β, which made the perfor-
mance of ChIP very difficult (data not shown). Therefore, 
it is possible that ESE-1 plays an indirect role or has other 
unknown function in COX-2 expression, such as mRNA 
stability, not just acting as a transcription factor, and the 
function of ESE-1 as a transcript, for example as a com-
peting endogenous RNA, has never been explored.
ESE‑1/Elf3 knockout (KO) macrophages also show 
increased COX‑2 mRNA expression
ESE-1 was previously shown to modulate COX-2 in 
RAW267.4 cells [17]. Therefore, to address the differ-
ence in cell type, we also examined COX-2 levels in 
ESE-1/Elf3 knockout (KO) bone marrow-derived mac-
rophages (BMDMs). Use of Elf3 KO BMDMs circum-
vented having to expose cells to additional inflammation 
from transfection- or transduction-mediated gene 
manipulation. In vitro differentiated BMDMs by CD11b 
and F4/80 staining were almost 100  % pure (Fig.  5a), 
and Elf3 KO BMDMs showed no defect in macrophage 
differentiation which could affect its function [28], 
Fig. 3 ESE‑1 is expressed in the nucleus of RASFs. a ESE‑1 protein level increases with IL‑1β stimulation (n = 4), shown by Western blot on whole 
cell lysates (WCLs) of stimulated or unstimulated RASFs. #1–#4 denotes patients #50, 58, 77, and 22, and A549 lysate was included as positive control 
for ESE‑1 protein. b ESE‑1 protein is exclusively expressed in the nucleus, with Hsp90 and Lamin A as cytoplasmic and nuclear markers, respectively. 
Western blot of nuclear fractionated RASFs stimulated with 10 ng/mL IL‑1β for 24 h. c ESE‑1 and COX‑2 are minimally present in RASFs without IL‑1β 
stimulation. d Knockdown of ESE‑1 by HD‑Ad‑shESE‑1 leads to increase in COX‑2 expression in the cytoplasm in IL‑1β treatment in RASFs compared 
to C4HSU control vector. Western blot showing results from two different patient RASFs
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expressing normal levels of M-CSFR, Ly-6G, and Ly-6C 
(data not shown). When subjected to LPS, however, 
Elf3 KO BMDMs showed increased transcriptional 
level of COX-2 (Fig. 5b). There are two discrete classes 
of macrophages, namely M1, which is proinflammatory 
or classically activated, and M2, which is alternatively 
activated and takes on more immune-regulatory role. 
Classically activated M1 macrophages have increased 
production of pro-inflammatory cytokines such as 
TNF-α and IL-12, IL-23, nitric oxide (NO), and reac-
tive oxygen species (ROS) and have increased antigen 
presentation and microbicidal activity, while M2 mac-
rophages typically produce anti-inflammatory cytokines 
such as IL-10, IL-1 receptor antagonist (IL-1rα) and 
promote tissue remodeling and repair [37]. Because 
COX-2 is one of the hallmark genes of M1 [37, 38], 
we also checked other genes related to M1- versus 
M2-polariation and observed that Elf3 KO BMDMs 
were slightly skewed towards M1 (Fig.  5c, d) by polar-
ization-specific gene expression. A single knockout of 
Elf3 out of almost 30 Ets factors, however, may not show 
a dramatic effect due to compensation from other Ets, 
which adds complexity. Elf3 KO BMDMs in fact tended 
to have more Peas3 and Elf5 and KO lungs expressed 
higher levels of Erm (data not shown). Nevertheless, it 
is first time showing ESE-1 can have anti-inflammatory 
COX-2























































































































Fig. 4 ESE‑1 downregulation leads to increased COX‑2 mRNA in SW982 cell line. a Analysis of ESE‑1, COX‑2, RelA and NFκB1 transcriptional levels 
by RT‑qPCR in SW982 cells during IL‑1β (10 ng/mL) stimulation. b Representative Western blot of SW982 stimulated with IL‑1β (10 ng/mL) over 
the 24 h time period. c Time course analysis of SW982 cells transduced with C4HSU or shESE‑1 HD‑Ad vectors and stimulated with IL‑1β over 24 h, 
started 72 h post‑transduction. *P < 0.05, **P < 0.01, ***P < 0.001, by one‑way ANOVA Bonferroni’s post‑test, data shown are representative of two 
independent experiments with n = 3 each
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role in macrophages which may be subjected to further 
analysis.
Discussion
It is undisputable that understanding the pathogen-
esis of RA is critical for its prevention and treatment. 
However, persistent inflammation arises not only 
from persistent elicitation but also from incomplete 
resolution, and in pursuit of finding causative mecha-
nisms, primary focus on effectors of pro-inflammatory 
response may have left some effectors playing dual 
or complex roles unrecognized from experimental 
approaches chosen to demonstrate one relationship but 
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Fig. 5 ESE‑1 knockout (KO) bone marrow derived macrophages (BMDMs) show increased COX‑2 expression and an increased propensity towards 
M1 phenotype. a Expression of macrophage maturation markers CD11b and F4/80 in BMDMs derived from WT or Elf3 KO C57BL/6 mice. Bone mar‑
row cells isolated from the WT or Elf3 mice were differentiated ex vivo in 20 % L‑929‑conditioned media and analyzed by flow cytometry. The graph 
shows n = 12 for WT and KO mice. b ESE‑1 knockout BMDMs show increased COX‑2 mRNA following LPS (100 ng/mL) treatment. BMDMs were 
plated at 4 x 105/well on 6‑well plates and stimulated with 100 ng/mL LPS or 10 ng/mL IL‑4 for 18 h, after which they were lysed for RNA isolation 
and qPCR analysis (n = 6). c shows mRNA expression of genes related to M1 polarization and d M2‑related genes in WT and KO BMDMs (n = 6) 
treated with 100 ng/mL LPS (“M1”) and 10 ng/mL IL‑4 (“M2) for 18 h prior to analysis. Statistical analysis by one‑way ANOVA with Bonferroni’s post‑
test for selected pairs, ns = not significant, *P < 0.05, **P < 0.01
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with an Ets transcription factor, ESE-1. ESE-1 was pre-
viously shown to co-operate with NFκB and positively 
regulate COX-2 by binding to the Ets-binding site on 
the COX-2 promoter [17]. However, by gene knock-
down approach, we made an opposite observation in 
human RASFs, where knockdown of ESE-1 led to an 
upregulation of COX-2, which correlated with increased 
levels of PGE2. The use of HD-Ad-mediated knockdown 
is advantageous over previously employed conventional 
transfections, given its higher efficacy of gene delivery 
and long-term expression, as well as much lower cellu-
lar toxicity and immunogenicity.
It is important to note that previous findings on ESE-1 
have been based on overexpression studies, but with 
insufficient consideration on the effect of the transfec-
tion procedure itself. Ectopic gene expression can lead to 
supraphysiological levels of the gene of interest, as well as 
cell toxicity from the transfection. Also, overexpression 
by transfection may not accurately reflect the temporal 
behavior of a protein, and may thus lead to artificial inter-
action or co-localization of proteins that normally do not 
co-exist under physiological conditions. For example, 
in RASFs, NFκB is resolved within 4  h following IL-1β 
stimulation [29], yet the effect of ESE-1 knockdown was 
only evident at 24 h time point, when the initial inflam-
mation induced by IL-1β had mostly resolved and ESE-1 
and NFκB were disparately localized in the nucleus and 
cytoplasm, respectively. Also, knockdown of ESE-1 had 
no effect on COX-2 induction in RASF or SW982, indi-
cating that ESE-1 may not play a direct role in regulating 
COX-2 transcription as previously thought. Rather, given 
that PGE2 has been shown to prolong COX-2 mRNA 
half-life through the p38 MAPK pathway, ESE-1 may be 
functioning more as a downstream effector of PGE2 sign-
aling than IL-1β at the 24-h time point. In fact, transcrip-
tional activation of COX-2 in NIH 3T3 fibroblasts by 
PGE2 was found to require C/EBP and CRE-1 sites but 
not NFκB [39], suggesting that ESE-1 may be interacting 
with protein partners other than NFκB or assuming other 
functions at later time points.
COX-2 regulation is complex, and occurs at both tran-
scriptional and non-transcriptional levels. The exact 
transcription factor complexes that are recruited at 
the COX-2 promoter site vary by cell type and stimula-
tion [40]. Sequence analysis of the 5′-flanking region of 
the human COX-2 gene has identified several poten-
tial transcriptional regulatory elements, including two 
nuclear factor kappa B (NF-κB) sites, an SP1 site, a 
CAAT enhancer binding protein (C/EBP), nuclear fac-
tor for interleukin-6 expression (NF-IL6) motif, two AP-2 
sites, an E-box, and a TATA-box, as well as a peroxisome 
proliferator response element (PPRE), two cyclic AMP 
response elements (CRE), and a sterol response element 
(SRE) [41]. Additionally, COX-2 can be regulated post-
transcriptionally by its mRNA stability with the involve-
ment of molecules such as HuR, microRNA 101a and 
199a and alternative polyadenylation [42] and by long-
noncoding RNAs [43], as well as at its protein level by 
N-glycosylation at Asn-594 and by substrate-dependent 
suicide inactivation [44]. Therefore, elucidation of the 
exact role of ESE-1 in COX-2 regulation warrants a sepa-
rate study.
However, one possible mechanism by which ESE-1 
exerts its repressor function on COX-2 transcription may 
be through ESE-3, another closely related Ets factor and 
a direct target gene of ESE-1. Unlike ESE-1 which typi-
cally peaks at 2 h following cytokine stimulation, ESE-3 
was found to peak around 24 h in human airway epithe-
lial cells [23]. While Wu et al. did not consider the pos-
sibility of ESE-3 acting as a reciprocal repressor of ESE-1, 
their data indicates that overexpression of ESE-3 was 
in fact more effective in inhibiting ESE-1 transcription 
than ESE-1 itself [23]. Similarly, p38 MAPK plays a cru-
cial role in prolonging COX-2 mRNA stability by PGE2 
[45, 46], and ESE-3 is known to act as a downstream 
repressor of p38 MAPK pathway under certain condi-
tions [47]. Therefore, it is possible that ESE-3 acts as a 
reciprocal repressor of ESE-1 at later time point when 
IL-1β is degraded, and that this feedback loop is defec-
tive in RASFs. Given that ESE-3 is also upregulated dur-
ing stress-induced senescence in human fibroblasts [48], 
dysregulation in the ESE-1-ESE-3-MAPK regulatory loop 
may be involved in sustaining the non-senescent pheno-
type of RASFs.
Lastly, although knockdown of ESE-1 also resulted in 
upregulation of COX-2 in SW982 cells, the pattern of 
ESE-1 expression induced by IL-1β was very different, 
indicating SW982 is not a truly representative model to 
study the role ESE-1 in human RASFs in vitro. Because 
most of the ESE-1 targets have been identified in immor-
talized cell lines, this points to the need to develop bet-
ter cell model systems that more closely mimic RASFs 
in  situ, as well as experimental tools which minimally 
interfere with immune-responsive function of the target 
proteins. Nonetheless, our findings reveal new insights 
into the role of ESE-1 in rheumatoid arthritis, as it is 
the first time to demonstrate that ESE-1 may assume an 
anti-inflammatory role under physiological conditions 
to prevent excessive tissue damage during an inflamma-
tory response, by negatively regulating COX-2 in human 
RASFs.
Conclusions
ESE-1 acts as a negative regulator of COX-2 in human 
RASFs and its effect on COX-2 is NFκB-independent, 
occurring at later phases of an inflammatory response. 
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This may indicate that ESE-1 is involved in the resolution 
of inflammation unlike previously thought, and this dis-
crepancy may be attributed to confounding responses to 
transfection procedures.
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